Lincoln Pharmaceuticals Limited
NSE: LINCOLN · Pharmaceuticals
Snapshot
Unlock Lincoln Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lincoln Pharmaceuticals Limited is an Indian company engaged in the manufacturing and trading of a diverse range of pharmaceutical products. Its portfolio spans multiple therapeutic areas, including dermatology, gynaecology, gastrointestinal, and sterile ophthalmic preparations.
Business Model
The company generates revenue through the production and sale of branded generics and pharmaceutical formulations across domestic and international markets. It leverages a broad product pipeline to serve various medical specialities.
- Founded:1979
Growth Outlook
Growth is driven by the expansion of its branded generics portfolio and the continued development of specialised therapeutic products. The company aims to strengthen its market presence through its diverse manufacturing capabilities.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and regulatory inspections by domestic and international health authorities.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins for pharmaceutical manufacturers.
- Market Competition. The highly fragmented Indian pharmaceutical sector presents intense competition from both large multinational corporations and smaller domestic players.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) can disrupt production schedules and affect overall profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Lincoln Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹694 Cr
TTM · consolidated
NET PROFIT
₹96 Cr
TTM · consolidated
EPS
₹48.16
TTM · consolidated
RETURN ON EQUITY
13.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.5%
TTM · consolidated
P/E
12.9x
Q1 FY27 · consolidated
EV/EBITDA
8.5x
Q1 FY27 · consolidated
EBITDA MARGIN
20.7%
TTM · consolidated
NET PROFIT MARGIN
20.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Lincoln Pharmaceuticals LimitedLINCOLN | ₹1,243 Cr | 12.89 | 8.53 | 10.2% | 20.7% | 13.5% | 17.5% | +12.9% |
Sigachi Industries LimitedSIGACHI | ₹1,327 Cr | 51.85 | 28.02 | -9.6% | 10.9% | 4.7% | 6.0% | +11.0% |
KopranKOPRAN | ₹1,123 Cr | 44.98 | 20.09 | 12.0% | 9.1% | 4.8% | 7.7% | +37.7% |
Themis MedicareTHEMISMED | ₹1,109 Cr | 27.75 | -36.75 | -12.8% | -9.9% | 10.0% | 11.3% | +20.2% |
Bajaj HealthcareBAJAJHCARE | ₹1,082 Cr | 59.53 | 11.01 | 12.3% | 18.5% | 3.5% | 9.3% | -24.7% |
Bharat Parenterals LimitedBPLPHARMA | ₹1,057 Cr | 37.27 | 16.39 | 9.4% | 21.2% | 8.3% | 9.0% | +10.9% |
As of Q1 FY27
Financials
Lincoln Pharmaceuticals Limited
NSE: LINCOLN · Pharmaceuticals
Snapshot
Unlock Lincoln Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lincoln Pharmaceuticals Limited is an Indian company engaged in the manufacturing and trading of a diverse range of pharmaceutical products. Its portfolio spans multiple therapeutic areas, including dermatology, gynaecology, gastrointestinal, and sterile ophthalmic preparations.
Business Model
The company generates revenue through the production and sale of branded generics and pharmaceutical formulations across domestic and international markets. It leverages a broad product pipeline to serve various medical specialities.
- Founded:1979
Growth Outlook
Growth is driven by the expansion of its branded generics portfolio and the continued development of specialised therapeutic products. The company aims to strengthen its market presence through its diverse manufacturing capabilities.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and regulatory inspections by domestic and international health authorities.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins for pharmaceutical manufacturers.
- Market Competition. The highly fragmented Indian pharmaceutical sector presents intense competition from both large multinational corporations and smaller domestic players.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) can disrupt production schedules and affect overall profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Lincoln Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹694 Cr
TTM · consolidated
NET PROFIT
₹96 Cr
TTM · consolidated
EPS
₹48.16
TTM · consolidated
RETURN ON EQUITY
13.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.5%
TTM · consolidated
P/E
12.9x
Q1 FY27 · consolidated
EV/EBITDA
8.5x
Q1 FY27 · consolidated
EBITDA MARGIN
20.7%
TTM · consolidated
NET PROFIT MARGIN
20.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27